8G63
Ralimetinib (LY2228820) in complex with wild type EGFR
Summary for 8G63
Entry DOI | 10.2210/pdb8g63/pdb |
Descriptor | Epidermal growth factor receptor, ralimetinib (3 entities in total) |
Functional Keywords | kinase inhibitor, transferase, transferase-inhibitor complex, transferase/inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 37724.65 |
Authors | Chitnis, S.P.,Heppner, D.E. (deposition date: 2023-02-14, release date: 2023-10-11, Last modification date: 2024-04-24) |
Primary citation | Bhattacharjee, D.,Bakar, J.,Chitnis, S.P.,Sausville, E.L.,Ashtekar, K.D.,Mendelson, B.E.,Long, K.,Smith, J.C.,Heppner, D.E.,Sheltzer, J.M. Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. Cell Chem Biol, 30:1211-1222.e5, 2023 Cited by PubMed: 37827156DOI: 10.1016/j.chembiol.2023.09.013 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.5 Å) |
Structure validation
Download full validation report